查看购物车
  • Traditional Chinese
  • English
  • Japanese
2021-2031年亚太地区胃肠药物市场报告（范围、细分、动态和竞争分析）
市场调查报告书
商品编码
1819725

2021-2031年亚太地区胃肠药物市场报告（范围、细分、动态和竞争分析）

Asia Pacific Gastrointestinal Drugs Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 165 Pages | 订单完成后即时交付

价格

亚太地区胃肠药物市场预计将大幅成长，到 2031 年将达到 223.777 亿美元，高于 2023 年的 121.4518 亿美元。这一成长代表着 2023 年至 2031 年的年复合成长率(CAGR) 为 7.9%。

执行摘要和市场分析

亚太地区涵盖多个主要国家，包括中国、日本、印度、澳洲、韩国等。中国和印度庞大的人口规模，以及製药公司对该地区日益增长的兴趣，推动着市场的成长。此外，胃肠道疾病发生率的上升、医疗支出的增加以及医疗技术的进步，也进一步推动了胃肠道药物市场的发展。

市场区隔分析

亚太地区的胃肠药物市场可根据药物类别、应用、给药途径和配销通路进行细分：

1. 药品类别：市场分为几类，包括生物製剂、止泻药和泻药、酸中和剂、抗发炎药、止吐药和止吐药等。 2023年，生物製剂占据了最大的市场。

2. 应用：市场也按应用细分，包括肠躁症 (IBS)、发炎性溃疡性结肠炎、克隆氏症、胃肠炎、乳糜泻等疾病。 2023 年，IBS 细分市场占据最大份额。

3. 给药途径：市场分为口服和非注射给药途径。 2023年，口服给药领域占市场主导地位。

4.配销通路：分销管道包括医院药房、零售药房和线上药房，其中医院药房在2023年占据最大的市场份额。

市场展望

全球胃肠道疾病的发生率正在上升，这促使人们加大对旨在开发新治疗方法的研究资金投入。例如，耶鲁大学医学院每年从美国国家糖尿病、消化和肾臟疾病研究所（NIDDK）获得超过800万美元的资助，用于探索各种胃肠道疾病，包括发炎性肠道疾病（IBD）和肝病。同样，北卡罗来纳大学医学院每年也获得超过2000万美元的资助，用于专注于胃肠道和肝病的研究，这凸显了了解这些疾病并开发新疗法的重要性。

临床研究的最新进展，尤其是人工智慧 (AI) 的整合，正在改变胃肠医学的模式。 AI 越来越多地用于分析大型数据集，从而带来更个人化和有效的治疗方案。机器学习演算法可以识别治疗反应的预测标记，从而为个别患者制定最佳化的治疗策略。

人工智慧也在增强胃肠医学的诊断影像。透过运用深度学习演算法，研究人员可以高精度地分析医学影像，例如CT扫描和内视镜影像，有助于早期发现胃肠道异常。例如，人工智慧在大肠镜检查中诊断结直肠息肉方面已显示出良好的前景，并有望减少不必要的手术干预。在纽卡斯尔永久慈善基金会等机构的资助下，研究人员正在探索人工智慧在开发发炎性肠道疾病（IBD）和溃疡性结肠炎新疗法中的应用，并专注于肠道微生物群和肠道干细胞。

对新药开发和基于人工智慧的方法的研究投入不断增加，有望为胃肠道疾病带来创新的治疗方案，塑造胃肠道药物市场的未来趋势。

国家洞察

亚太胃肠药物市场的特点是各国做出了巨大贡献，其中中国将在 2023 年引领市场。中国的成长可归因于其庞大的人口、胃肠疾病盛行率的上升、药品销售额的增加以及支持性的监管框架。

中国正积极加强医疗基础建设，并开发各种医药产品。最近的一项研究表明，中国肠躁症（IBS）的盛行率为3.2%至17.7%，凸显了胃肠道疾病给中国带来的沉重负担。为此，中国政府实施了中国胃肠道健康指数（GHI）等倡议，以监测和控制这些疾病的发生率，旨在提高预期寿命并改善医疗资源分配。

本土和国际製药公司在中国的布局正在促进市场成长。例如，2023年9月，EA Pharma Co., Ltd. 和 TransThera Sciences, Inc. 宣布建立策略伙伴关係，共同开发针对胃肠道发炎疾病的先进疗法，彰显了其在该领域创新的决心。

公司简介

亚太胃肠药物市场的主要参与者包括赛诺菲公司、葛兰素史克公司、强生公司、博士伦健康公司、阿斯特捷利康公司、武田製药有限公司、艾伯维公司、拜耳公司和辉瑞公司。这些公司正在推行各种策略，包括扩张、产品创新和併购，以增强其市场占有率并为消费者提供创新解决方案。

目录

第一章：简介

第二章：执行摘要

  • 关键见解

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第四章：亚太胃肠药物市场－主要市场动态

  • 市场驱动因素
    • 胃肠道疾病病例增加
    • 生物製剂的不断发展
  • 市场限制
    • 生物製剂成本高
    • 治疗严重溃疡性结肠炎或克隆氏症的生物製剂平均费用
  • 市场机会
    • 公司的策略倡议
  • 未来趋势
    • 加大对新药开发与人工智慧技术的研究投入
  • 驱动因素和限制因素的影响：

第五章：胃肠药物市场－亚太地区分析

  • 2021-2031年亚太地区胃肠药物市场收入

第六章：亚太胃肠药物市场分析－依药物类别

  • 生物製剂
  • 止泻药和泻药
  • 酸中和剂
  • 抗发炎药物
  • 止吐药和止噁心药
  • 其他的

第七章：亚太胃肠药物市场分析-按应用

  • 急躁性肠症候群
  • 发炎性溃疡性结肠炎
  • 克罗恩病
  • 胃肠炎
  • 乳糜泻
  • 其他的

第八章：亚太胃肠药物市场分析－依给药途径

  • 口服
  • 肠外

第九章：亚太胃肠药物市场分析-按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第十章：亚太胃肠药物市场－国家分析

  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区

第 11 章：产业格局

  • 概述
  • 亚太胃肠药物市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第十二章：公司简介

  • Sanofi SA
  • GSK Plc
  • Johnson & Johnson
  • Bausch Health Companies Inc
  • AstraZeneca Plc
  • Takeda Pharmaceutical Co Ltd
  • AbbVie Inc
  • Bayer AG
  • Celltrion Inc
  • Pfizer Inc

第 13 章：附录

Product Code: TIPRE00016279

The Asia Pacific gastrointestinal drugs market is projected to grow significantly, reaching an estimated US$ 22,377.77 million by 2031, up from US$ 12,145.18 million in 2023. This growth represents a compound annual growth rate (CAGR) of 7.9% from 2023 to 2031.

Executive Summary and Market Analysis

The Asia Pacific region encompasses several key countries, including China, Japan, India, Australia, South Korea, and others. The substantial populations in China and India, along with the increasing interest from pharmaceutical companies in this region, are driving market growth. Additionally, the rising incidence of gastrointestinal disorders, increased healthcare expenditure, and advancements in medical technology are further propelling the gastrointestinal drugs market.

Market Segmentation Analysis

The gastrointestinal drugs market in Asia Pacific can be segmented based on drug class, application, route of administration, and distribution channel:

1. Drug Class: The market is divided into several categories, including biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants, among others. In 2023, biologics accounted for the largest market share.

2. Application: The market is also segmented by application, which includes conditions such as irritable bowel syndrome (IBS), inflammatory ulcerative colitis, Crohn's disease, gastroenteritis, celiac disease, and others. The IBS segment held the largest share in 2023.

3. Route of Administration: The market is bifurcated into oral and parenteral routes. The oral administration segment dominated the market in 2023.

4. Distribution Channel: The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies holding the largest market share in 2023.

Market Outlook

The prevalence of gastrointestinal diseases is on the rise globally, prompting increased funding for research aimed at developing new treatment methods. For example, the Yale School of Medicine receives over US$ 8 million annually from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to explore various gastrointestinal disorders, including inflammatory bowel disease (IBD) and liver diseases. Similarly, the UNC School of Medicine has over US$ 20 million in annual funding for research focused on gastrointestinal and liver diseases, emphasizing the importance of understanding these conditions and developing new therapies.

Recent advancements in clinical research, particularly the integration of artificial intelligence (AI), are transforming the landscape of gastrointestinal medicine. AI is increasingly utilized to analyze large datasets, leading to more personalized and effective treatment options. Machine learning algorithms can identify predictive markers for treatment responses, allowing for optimized therapeutic strategies tailored to individual patients.

AI is also enhancing diagnostic imaging in gastrointestinal medicine. By employing deep learning algorithms, researchers can analyze medical images, such as CT scans and endoscopic images, with high precision, facilitating early detection of gastrointestinal abnormalities. For instance, AI has shown promise in diagnosing colorectal polyps during colonoscopy, potentially reducing unnecessary surgical interventions. With funding from organizations like the Newcastle Permanent Charitable Foundation, researchers are exploring AI applications in developing new therapies for IBD and ulcerative colitis, focusing on the gut microbiome and intestinal stem cells.

The increasing investment in research for novel drug development and AI-based methodologies is expected to introduce innovative treatment solutions for gastrointestinal conditions, shaping future trends in the gastrointestinal drugs market.

Country Insights

The Asia Pacific gastrointestinal drugs market is characterized by significant contributions from various countries, with China leading the market in 2023. The growth in China can be attributed to its large population, the rising prevalence of gastrointestinal diseases, increasing pharmaceutical sales, and supportive regulatory frameworks.

China is actively enhancing its healthcare infrastructure and developing various medicinal products. A recent study indicated that the prevalence of irritable bowel syndrome (IBS) in China ranges from 3.2% to 17.7%, highlighting the substantial burden of gastrointestinal diseases in the country. In response, the Chinese government has implemented initiatives like the China Gastrointestinal Health Index (GHI) to monitor and control the incidence of these diseases, aiming to improve life expectancy and healthcare resource distribution.

The presence of both local and international pharmaceutical companies in China is fostering market growth. For instance, in September 2023, EA Pharma Co., Ltd. and TransThera Sciences, Inc. announced a strategic collaboration to develop advanced therapeutics targeting inflammatory diseases of the gastrointestinal system, showcasing the commitment to innovation in this sector.

Company Profiles

Key players in the Asia Pacific gastrointestinal drugs market include Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, and Pfizer Inc. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and deliver innovative solutions to consumers.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Asia Pacific Gastrointestinal Drugs Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Cases of Gastrointestinal Diseases
    • 4.1.2 Increasing Development of Biologics
  • 4.2 Market Restraints
    • 4.2.1 High Cost of Biologics
    • 4.2.2 Average Cost of Biologic Drugs for Severe Ulcerative Colitis or Crohn's Disease
  • 4.3 Market Opportunities
    • 4.3.1 Strategic Initiatives by Companies
  • 4.4 Future Trends
    • 4.4.1 Increasing Research Investment for Novel Drug Development and Artificial Intelligence-Based Techniques
  • 4.5 Impact of Drivers and Restraints:

5. Gastrointestinal Drugs Market - Asia Pacific Analysis

  • 5.1 Asia Pacific Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031

6. Asia Pacific Gastrointestinal Drugs Market Analysis - by Drug Class

  • 6.1 Biologics
    • 6.1.1 Overview
    • 6.1.2 Biologics: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.2 Antidiarrheal and Laxatives
    • 6.2.1 Overview
    • 6.2.2 Antidiarrheal and Laxatives: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Acid Neutralizers
    • 6.3.1 Overview
    • 6.3.2 Acid Neutralizers: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Anti-inflammatory Drugs
    • 6.4.1 Overview
    • 6.4.2 Anti-inflammatory Drugs: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.5 Antiemetic and Antinauseants
    • 6.5.1 Overview
    • 6.5.2 Antiemetic and Antinauseants: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

7. Asia Pacific Gastrointestinal Drugs Market Analysis - by Application

  • 7.1 Irritable Bowel Syndrome
    • 7.1.1 Overview
    • 7.1.2 Irritable Bowel Syndrome: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Inflammatory Ulcerative Colitis
    • 7.2.1 Overview
    • 7.2.2 Inflammatory Ulcerative Colitis: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Crohn's Disease
    • 7.3.1 Overview
    • 7.3.2 Crohn's Disease: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Gastroenteritis
    • 7.4.1 Overview
    • 7.4.2 Gastroenteritis: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Celiac Disease
    • 7.5.1 Overview
    • 7.5.2 Celiac Disease: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Gastrointestinal Drugs Market Analysis - by Route of Administration

  • 8.1 Oral
    • 8.1.1 Overview
    • 8.1.2 Oral: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Parenteral
    • 8.2.1 Overview
    • 8.2.2 Parenteral: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Gastrointestinal Drugs Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Retail Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Online Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Online Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. Asia Pacific Gastrointestinal Drugs Market - Country Analysis

  • 10.1 Asia Pacific
    • 10.1.1 Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.1.1 China: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.1.2 China: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.1.3 China: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.1.4 China: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.2 Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.1 Japan: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.2.2 Japan: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.2.3 Japan: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.2.4 Japan: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.3 India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.1 India: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.3.2 India: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.3.3 India: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.3.4 India: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.4 Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.1 Australia: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.4.2 Australia: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.4.3 Australia: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.4.4 Australia: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.5 South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.5.1 South Korea: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.5.2 South Korea: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.5.3 South Korea: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.5.4 South Korea: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.6 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.6.1 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.6.2 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.6.3 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.6.4 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Asia Pacific Gastrointestinal Drugs Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Sanofi SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 GSK Plc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Johnson & Johnson
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Bausch Health Companies Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 AstraZeneca Plc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Takeda Pharmaceutical Co Ltd
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AbbVie Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Bayer AG
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Celltrion Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Pfizer Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Asia Pacific Gastrointestinal Drugs Market Segmentation
  • Table 2. China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 3. China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 4. China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 5. China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 6. Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 7. Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 8. Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 9. Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 10. India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 11. India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 12. India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 13. India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 14. Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 15. Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 16. Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 17. Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 18. South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 19. South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 20. South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 21. South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 22. Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 23. Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 24. Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 25. Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 26. Recent Organic Growth Strategies in Asia Pacific Gastrointestinal Drugs Market
  • Table 27. Recent Inorganic Growth Strategies in the Asia Pacific Gastrointestinal Drugs Market
  • Table 28. Glossary of Terms, Asia Pacific Gastrointestinal Drugs Market

List Of Figures

  • Figure 1. Asia Pacific Gastrointestinal Drugs Market Segmentation, by Country
  • Figure 2. Asia Pacific Gastrointestinal Drugs Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Asia Pacific Gastrointestinal Drugs Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 6. Biologics: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Antidiarrheal and Laxatives: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Acid Neutralizers: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Anti-inflammatory Drugs: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Antiemetic and Antinauseants: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Others: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Asia Pacific Gastrointestinal Drugs Market Share (%) - by Application (2023 and 2031)
  • Figure 13. Irritable Bowel Syndrome: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Inflammatory Ulcerative Colitis: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Crohn's Disease: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Gastroenteritis: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Celiac Disease: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Others: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Asia Pacific Gastrointestinal Drugs Market Share (%) - by Route of Administration (2023 and 2031)
  • Figure 20. Oral: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Parenteral: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Asia Pacific Gastrointestinal Drugs Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 23. Hospital Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Retail Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Online Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Asia Pacific Gastrointestinal Drugs Market Breakdown, by Key Countries - Revenue (2023) (US$ Million)
  • Figure 27. Asia Pacific Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 28. China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 29. Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Growth Strategies in Asia Pacific Gastrointestinal Drugs Market